Xenetic Biosciences to be acquired by Santersus in all-stock deal; shares fall 49%

What happened

Xenetic Biosciences, Inc. (Nasdaq: XBIO), a small Massachusetts-based drug developer, announced on September 16, 2026 that it has signed a definitive Share Exchange Agreement to be acquired by Santersus AG, a privately held Swiss company, according to press releases carried by Yahoo Finance and BioSpace and confirmed in coverage by TradingView.

Under the deal, Xenetic will acquire the outstanding share capital of Santersus and issue shares as consideration, which is why the announcement describes it as a stock-for-stock exchange. Coverage by TradingView states that, after the transaction, Santersus shareholders are expected to own roughly 85% of the combined company. The combined business is expected to be renamed Santersus Bio, Inc. and be headquartered in Framingham, Massachusetts, according to a press release reported by BioSpace.

MarketScreenr's report describes the transaction value at $120 million. Xenetic also held an M&A call on the morning of the announcement, according to a transcript published by Seeking Alpha.

The stock closed at $2.19, down 48.71% from the prior close of $4.27 — a decline that outpaced the roughly 32% premarket drop discussed earlier in the day on social media.

Why the stock fell

In an all-stock acquisition, the buyer issues new shares to the seller's owners. When a much larger private company is folded into a much smaller public one, the seller's shareholders typically end up owning most of the combined company. The TradingView report puts the Santersus side's expected ownership at about 85%, which means existing Xenetic shareholders would be left with roughly 15% of the company they currently own.

That math is the central fact investors were reacting to. Pre-announcement, Xenetic's stock traded around $4.27; after the deal was disclosed, it closed at $2.19. The share count Xenetic holders currently own is not changing, but the slice of the business each share represents is. This dilution of ownership is the mechanical reason an all-stock deal for a much smaller listed company usually moves the listed company's stock sharply lower on announcement day.

The reports do not state that Xenetic was under any pressure to sell, and no source says the deal was negotiated from a position of weakness. The filings underlying the announcement — the 8-K referenced by StockTitan — have not yet been reviewed for this article, so the deal's specific exchange ratio, closing conditions, and termination provisions are not cited here.

What this means

Xenetic Biosciences is a clinical-stage pharmaceutical company. Its stock trades on Nasdaq under the ticker XBIO. Companies at this stage usually have little or no product revenue and fund themselves by selling stock. As of this writing, Xenetic's day-to-day business centers on a pipeline of drug candidates, and the announcement says the combined company will focus on what the press release calls NET-targeting therapeutics — NET stands for neutrophil extracellular traps, a structure the immune system uses to fight infection.

Santersus AG is a private company based in Switzerland. Because it is not listed, its shares do not trade on an exchange; a US investor cannot buy them directly. The Share Exchange Agreement is the legal mechanism that converts Santersus's private shares into shares of the public Xenetic entity. In an all-stock exchange, no cash changes hands at the shareholder level. Instead, Xenetic issues new shares to Santersus's owners, and those owners become the majority owners of the combined, publicly traded company.

A Share Exchange Agreement is a contract, not a completed transaction. It sets out the terms, the conditions each side must satisfy, and the events that would let either side walk away. Shareholder votes and regulatory clearances are still required, and the reports indicate the deal is intended to be tax-free, which is a common structuring goal in all-stock exchanges between US and foreign companies. Until those steps are complete, Xenetic remains an independent, publicly traded company, and the combined company does not yet exist.

If the closing conditions are satisfied and the transaction closes, Xenetic's corporate identity would continue but its ownership and name would change. The ticker might change as well; the public materials do not specify that detail. For an existing Xenetic holder, the economic outcome is the same either way: their shares would represent a smaller percentage of a larger enterprise. The market's price reaction on announcement day — a 48.71% single-day decline — reflects the market's attempt to mark the stock to that smaller percentage.